Fixed twelve weeks duration versus response tailored course of dual Sofosbuvir/Daclatasvir therapy in Egyptian adult and adolescent patients with chronic hepatitis C infection (HCV).
Phase 3
Completed
- Conditions
- chronic virus hepatitis C infection
- Registration Number
- ACTRN12617000263392
- Lead Sponsor
- Green CRC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method